XP5

XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM) . XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma[1].

Product Specifications

CAS Number

[2760511-91-7]

UNSPSC

12352005

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/xp5.html

Solubility

10 mM in DMSO

Smiles

COC1=CC=C(C(OC)=C1)C2=NC=C(S2)C(NCCCCCCC(NO)=O)=O

Molecular Formula

C19H25N3O5S

Molecular Weight

407.48

References & Citations

[1]Peng X, et al. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. J Med Chem. 2022;65 (3) :2434-2457.